1Kon SS,Canavan JL, Man WD. Pulmonary rehabilitation and acute exac- erbations of COPD [ J -. Expert Rev Respir Med,2012 ; 6 ( 5 ) : 523-31.
2Wu J, Ding C, Ge Q, et al. Simultaneous determination of ipratropium andsalbutamol in rat plasma by LC-MS/MS and its application to a pharma- cokinetic study [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2011 ; 879 ( 30 ) :3475-83.
4Zhong N, Wang C, Yao W, et al. Prevalence of chnnic obstructive pulmonary lisease in China; a large, peoplelation - baded survey. Respir Crit Care Med,2007,176:753 - 760.
5Akkoca Yildi2 O, Onen 2P, DmikG, et. al. Is there any difference brtween effects of ipratropium bromide and formiterol on exercise capacity in moderate COPD. patient? Tuberk Toraks ,2006,54 : 105 - 113.
6Hanania NA, Donohue. JF. Phanmacologic interventions in chrinic obstractive pulmonary disease: bronchodilators. Proc Am Tlaorac Soc ,2007,4:526 - 534.
7Snow V, Laschor S, Mottur-Pilson C, etal. The evidence base for management of cecute exacerbations of COPD: clinical practive guideline,part I. echest,2001,119:1185 - 1190.
8Tennant RC, Erin EM, Barnesy PJ, et al. Long-acting b2-adrenoceptor agonists or tiotropium bromide for patients with COPD:is combination therapy justified[J]. Current Opinion in Pharmacology, 2003,3 :270-276.
9Johnson M. Beta 2-adrenoceptors: mechanisms of action of beta 2-agonists[J]. Paediatric Respiratory Reviews, 2001,2:57-62.
10Billington CK,Penn RB. M3 muscarinic acetylcholine receptor regulation in the airway[J]. Am J Respir Cell Mol Biol, 2002,26 : 269-272.
